Soligenix, Inc. (SNGX) announced on Monday that its SGX945 or Dusquetide development program for oral lesions of Behçet's Disease has received a 'Fast Track' designation from the FDA.
PRINCETON, N.J., Jan. 8, 2024 /PRNewswire/ Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an.
Clinical Success Achieved in Second Cohort of Patients
PRINCETON, N.J., Jan. 4, 2024 /PRNewswire/ Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and.